PharmacyCodes



Lercanidipine [Inn] en es it fr

Lercanidipine [Inn] Brand names, Lercanidipine [Inn] Analogs

Lercanidipine [Inn] Brand Names Mixture

  • No information avaliable

Lercanidipine [Inn] Chemical_Formula

C36H41N3O6

Lercanidipine [Inn] RX_link

No information avaliable

Lercanidipine [Inn] fda sheet

Lercanidipine [Inn] msds (material safety sheet)

Lercanidipine [Inn] Synthesis Reference

No information avaliable

Lercanidipine [Inn] Molecular Weight

611.727 g/mol

Lercanidipine [Inn] Melting Point

No information avaliable

Lercanidipine [Inn] H2O Solubility

No information avaliable

Lercanidipine [Inn] State

Solid

Lercanidipine [Inn] LogP

7.16

Lercanidipine [Inn] Dosage Forms

No information avaliable

Lercanidipine [Inn] Indication

For the treatment of Hypertension and management of angina pectoris and Raynaud's syndrome

Lercanidipine [Inn] Pharmacology

Lercanidipine, a dihydropyridine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Lercanidipine is similar to other peripheral vasodilators. Lercanidipine inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.

Lercanidipine [Inn] Absorption

No information avaliable

Lercanidipine [Inn] side effects and Toxicity

No information avaliable

Lercanidipine [Inn] Patient Information

No information avaliable

Lercanidipine [Inn] Organisms Affected

Humans and other mammals